Jack Nathan Medical (JNHMF) Ratios

4 Followers

Jack Nathan Medical Ratios

JNHMF's free cash flow for Q1 2026 was C$0.83. For the 2026 fiscal year, JNHMF's free cash flow was decreased by C$ and operating cash flow was C$-0.41. See a summary of the company’s cash flow.

Ratios	TTM	Apr 25	Jan 24	Apr 23	Apr 22
Liquidity Ratios
Current Ratio	―	1.81	0.91	0.45	8.49
Quick Ratio	―	1.81	0.91	0.45	8.61
Cash Ratio	―	1.27	0.49	0.26	8.01
Solvency Ratio	―	3.75	-0.32	-0.72	-3.42
Operating Cash Flow Ratio	―	-3.69	-0.97	-0.36	-0.84
Short-Term Operating Cash Flow Coverage	―	-108.17	-3.04	-0.94	-4.03
Net Current Asset Value	C$ ―	C$ 912.15K	C$ -11.38M	C$ -5.80M	C$ 6.02M
Leverage Ratios
Debt-to-Assets Ratio	―	0.07	1.11	0.71	0.07
Debt-to-Equity Ratio	―	0.18	-2.08	-2.44	0.08
Debt-to-Capital Ratio	―	0.16	1.92	1.70	0.08
Long-Term Debt-to-Capital Ratio	―	0.00	2.54	-8.24	0.01
Financial Leverage Ratio	―	2.68	-1.88	-3.45	1.25
Debt Service Coverage Ratio	―	-12.71	-2.06	-2.14	-19.13
Interest Coverage Ratio	―	-39.03	0.00	-12.95	-41.29
Debt to Market Cap	―	<0.01	3.45	0.56	0.02
Interest Debt Per Share	―	<0.01	0.14	0.06	0.01
Net Debt to EBITDA	―	1.27	-1.88	-0.56	0.93
Profitability Margins
Gross Profit Margin	―	84.66%	75.62%	76.31%	71.84%
EBIT Margin	―	-27.45%	-32.04%	-42.48%	-83.54%
EBITDA Margin	―	-17.68%	-25.88%	-35.57%	-78.17%
Operating Profit Margin	―	-28.48%	-33.66%	-34.25%	-77.89%
Pretax Profit Margin	―	-28.88%	-38.87%	-45.13%	-85.41%
Net Profit Margin	―	85.74%	-34.66%	-45.69%	-81.00%
Continuous Operations Profit Margin	―	-29.06%	-34.66%	-44.57%	-83.16%
Net Income Per EBT	―	-296.92%	89.17%	101.26%	94.84%
EBT Per EBIT	―	101.39%	115.49%	131.74%	109.66%
Return on Assets (ROA)	―	210.68%	-59.32%	-109.70%	-73.30%
Return on Equity (ROE)	―	563.81%	111.59%	378.90%	-91.50%
Return on Capital Employed (ROCE)	―	-136.45%	-131.62%	-632.28%	-77.47%
Return on Invested Capital (ROIC)	―	-128.16%	-80.01%	-159.45%	-71.67%
Return on Tangible Assets	―	210.68%	-64.75%	-137.20%	-82.27%
Earnings Yield	―	100.00%	-193.96%	-104.94%	-47.48%
Efficiency Ratios
Receivables Turnover	―	15.66	7.66	17.34	10.97
Payables Turnover	―	0.80	1.17	1.17	1.49
Inventory Turnover	―	0.00	0.00	0.00	-23.64
Fixed Asset Turnover	―	21.14	4.33	6.06	7.83
Asset Turnover	―	2.46	1.71	2.40	0.90
Working Capital Turnover Ratio	―	20.17	-10.52	7.57	2.54
Cash Conversion Cycle	―	-432.38	-265.52	-292.24	-226.46
Days of Sales Outstanding	―	23.30	47.66	21.04	33.29
Days of Inventory Outstanding	―	0.00	0.00	0.00	-15.44
Days of Payables Outstanding	―	455.68	313.18	313.29	244.30
Operating Cycle	―	23.30	47.66	21.04	17.85
Cash Flow Ratios
Operating Cash Flow Per Share	―	-0.03	-0.07	-0.02	>-0.01
Free Cash Flow Per Share	―	-0.03	-0.12	-0.05	-0.02
CapEx Per Share	―	<0.01	0.05	0.03	<0.01
Free Cash Flow to Operating Cash Flow	―	1.19	1.67	2.29	1.62
Dividend Paid and CapEx Coverage Ratio	―	-5.40	-1.49	-0.78	-1.62
Capital Expenditure Coverage Ratio	―	-5.40	-1.49	-0.78	-1.62
Operating Cash Flow Coverage Ratio	―	-26.15	-0.49	-0.44	-1.13
Operating Cash Flow to Sales Ratio	―	-0.73	-0.32	-0.13	-0.08
Free Cash Flow Yield	―	-101.03%	-298.05%	-68.08%	-7.96%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-1.03	-0.52	-0.95	-2.11
Price-to-Sales (P/S) Ratio	―	0.86	0.18	0.44	1.71
Price-to-Book (P/B) Ratio	―	5.64	-0.58	-3.61	1.93
Price-to-Free Cash Flow (P/FCF) Ratio	―	-0.99	-0.34	-1.47	-12.56
Price-to-Operating Cash Flow Ratio	―	-1.17	-0.56	-3.36	-20.32
Price-to-Earnings Growth (PEG) Ratio	―	0.02	0.07	0.08	0.04
Price-to-Fair Value	―	5.64	-0.58	-3.61	1.93
Enterprise Value Multiple	―	-3.58	-2.57	-1.78	-1.26
Enterprise Value	―	5.51M	12.75M	9.83M	9.47M
EV to EBITDA	―	-3.58	-2.57	-1.78	-1.26
EV to Sales	―	0.63	0.67	0.63	0.98
EV to Free Cash Flow	―	-0.73	-1.25	-2.14	-7.24
EV to Operating Cash Flow	―	-0.87	-2.09	-4.90	-11.70
Tangible Book Value Per Share	―	<0.01	-0.08	-0.04	0.09
Shareholders’ Equity Per Share	―	<0.01	-0.07	-0.02	0.10
Tax and Other Ratios
Effective Tax Rate	―	>-0.01	0.11	0.01	0.03
Revenue Per Share	―	0.03	0.22	0.18	0.12
Net Income Per Share	―	0.03	-0.08	-0.08	-0.09
Tax Burden	―	-2.97	0.89	1.01	0.95
Interest Burden	―	1.05	1.21	1.06	1.02
Research & Development to Revenue	―	0.00	0.00	0.02	0.06
SG&A to Revenue	―	1.09	0.91	0.46	0.85
Stock-Based Compensation to Revenue	―	<0.01	0.03	0.07	0.26
Income Quality	―	-0.85	0.92	0.29	0.08

Currency in CAD